PharmaTher Inc. is a specialty pharmaceutical company focused on repurposing psychedelic-derived drugs with artificial intelligence.
PharmaTher’s drug repurposing artificial intelligence platform, PanaceAI, combines multilayered processes and systems for integrating millions of data points and performing machine learning to discover new uses of psychedelic-based drugs. PanaceAI serves as PharmaTher’s product pipeline engine for psychedelic-derived drugs and it will unlock partnership opportunities with biotechnology and pharmaceutical companies seeking to expand their product pipeline.
PharmaTher has filed provisional patents for PanaceAI and certain neurological disorders. Currently, PharmaTher’s product pipeline targets neurological indications, such as traumatic brain injury, migraines and rare pediatric disorders, which all come with attractive U.S. Food and Drug Administration regulatory incentives for expedited approvals, such as orphan drug, fast track and breakthrough designations.
On June 4, 2020, Newscope Capital Corp. entered into an arms-length share exchange agreement whereby Newscope will acquire all of PharmaTher shares in exchange for the issues of an aggregate of 45.74 million common shares in the capital of Newscope at a price of $0.10 per Consideration Share.